Quercis Pharma AG is a privately owned, biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is advancing a development pipeline of late-stage clinical studies that focus on the prevention of VTE in cancer patients and sickle cell disease. In addition, Quercis plans to target cancers and other diseases associated with thrombotic events. The Company’s lead drug candidate acts as an anti-thrombotic with significantly lower risk of thrombosis and resulting adverse events than existing treatments. The Company also has a combination drug for cancer and neurological indications in development.